MITOGUARDER® Technology
Biologic and industrial protein production is expensive, yield limited and vulnerable to cell stress.
This stress limits production efficiency and quality of high-value proteins, such as biologics, diagnostic antibodies, protein/peptide hormones and vaccines.
Our innovative stress management platform, underpinned by a decade of pioneering scientific discoveries, dramatically reduces high costs related to host cell protein expression systems.
The missing puzzle piece across modern biotech
Turning stressed cells into high-performance biofactories for biologic and industrial protein production
An Open Secret across the Industry
💡Imagine sending a parcel in the post
This is like the production journey of each protein in cells, tiny protein factories.
First, cells follow instructions to produce proteins (parcels submitted at the post office). Then, biological features guide proteins throughout the cell (the parcel address label). Once production is complete, proteins arrive at their end destination (parcel delivery).
Cells are like postal delivery workers, already working hard to make sure that multiple proteins (parcels) are delivered to the right place and at the right time.
💡Now, imagine sending a parcel in the post at Christmas
This is like recombinant protein production in cells. In addition to their usual number of parcels (proteins), postal delivery workers (cells) now need to handle a huge increase in Christmas presents (recombinant proteins).
The result? Stressed out postal delivery workers, parcels delivered to the wrong place, arriving damaged, late or not at all.
Just like postal delivery workers at Christmas, cells producing recombinant proteins become tired, overwhelmed and stressed out, decreasing output quality and quantity.
The long-standing bottleneck in recombinant protein production
Solving the Biologics Bottleneck
When cells are pushed to high-yield, high-stress conditions, energy drops, protein misfolding increases and run time shortens
Our Solution
The Problem
MITOGUARDER® stress management platform boosts the energy profiles of cell biofactories, enabling faster, longer and more efficient manufacturing cycles.
Cell biofactories are pushed beyond their natural limits, becoming tired, overwhelmed and stressed out, capping yields and driving up costs over time.
Our stress management platform allows cells to maintain energy production and sustain biosynthetic capacity under heavy load
Tech Overview
MITOGUARDER® is a platform technology that drastically increases protein yield, production duration and cell viability by managing cell stress
What is Our Tech?
We have developed a routinely installable genetic setup that delivers benefits for any eukaryotic host cell system expressing relevant foreign proteins. MITOGUARDER® substantially boosts protein production across protein types (eg. antibodies, vaccines, 'difficult-to-express' and fusion proteins) and host cell expression systems.
What does Our Tech do?
MITOGUARDER® enhances productivity without process changes, for easy production chain incorporation. The result: longer active expression phase, higher yields, fewer batch inconsistencies and major reductions in cost of goods (COGS). This reduction in manufacturing costs, makes even the most cost-prohibitive proteins more viable at scale.
A more efficient path to meet pre-clinical and clinical milestones.
Therapeutic Proteins
Industrial Enzymes
Cell Line Developers
Vaccines & Viral Vectors
CDMOs & CROs
Improved supply chain resilience and scalability.
Unlock new stress-tolerant yeast strains, mammalian and insect lines.
Differentiate offerings by margin uplift and enabling new service titres.
Build higher-performing production strains from the ground up.
Our Tech Applications & Opportunities
✔️ Higher yields, no need for supplements or media changes.
✔️ Improved cost and sustainability margins.
✔️ Extended production runs reduce batch variability.
✔️ Cell expression host agnostic design for broad applicability.
✔️ Rapid, regulatory expectation aligned technology integration.
✔️ Enabling production of 'difficult-to-express' proteins.
Stage of Development
Our team is happy to tell you more!
For further enquiries, see our contact details on the Contact page.
We are working hard on transitioning our technology from academic proof to commercial piloting
Current State
✔️ Proof of concept: 4X yield versus current tech
✔️ IPR: FTO confirmed, priority patent filing in Q4 2025 via a leading European patent attorney firm
✔️ Prototype: robust proof of concept in hand, we are entering the prototype development phase
Seeking Partnerships
We're actively seeking partnerships across the protein production ecosystem. If you're looking to boost protein yield, cut production costs and gain a sustainable edge in biologics or enzyme discovery, developability or manufacturing, we'd love to work together to demonstrate how MITOGUARDER® technology can benefit you.
